Lise Lotte Hansen

Competitive amplification of differentially melting amplicons (CADMA) improves KRAS hotspot mutation testing in colorectal cancer

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Cancer is an extremely heterogeneous group of diseases traditionally categorized according to tissue of origin. However, even among patients with the same cancer subtype the cellular alterations at the molecular level are often very different. Several new therapies targeting specific molecular changes found in individual patients have initiated the era of personalized therapy and significantly improved patient care. In metastatic colorectal cancer (mCRC) a selected group of patients with wild-type KRAS respond to antibodies against the epidermal growth factor receptor (EGFR). Testing for KRAS mutations is now required prior to anti-EGFR treatment, however, less sensitive methods based on conventional PCR regularly fail to detect KRAS mutations in clinical samples.
Original languageEnglish
JournalB M C Cancer
Pages (from-to)548
Publication statusPublished - 2012

    Research areas

  • Cell Line, Tumor, Colorectal Neoplasms, DNA Mutational Analysis, DNA, Neoplasm, Humans, Mutation, Polymerase Chain Reaction, Proto-Oncogene Proteins, Reproducibility of Results, Sequence Analysis, DNA, ras Proteins

See relations at Aarhus University Citationformats

ID: 68515752